Holen Sie sich die Stockscreener-App
56.75
5.33%
-3.25
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
April 24th Options Now Available For CRISPR Therapeutics (CRSP) - Nasdaq
Citigroup Inc. Sells 88,203 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Amova Asset Management Americas Inc. Decreases Position in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG $CRSP is ARK Investment Management LLC's 8th Largest Position - MarketBeat
Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of - The Motley Fool
CRISPR Therapeutics AG $CRSP Position Raised by Vanguard Group Inc. - MarketBeat
Contrarius Group Holdings Ltd Sells 104,604 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
CRSP Stock Price and Chart — NASDAQ:CRSP - TradingView
Here’s What You Should Understand Besides the Reason CRISPR Therapeutics AG (CRSP) is Gaining Attention - Bitget
Is CRISPR Therapeutics Stock Too Risky to Buy Right Now? - The Motley Fool
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - Yahoo Finance
TD Asset Management Inc Sells 53,800 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Rafferty Asset Management LLC Has $10 Million Stock Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
Vertex Interest Renews CRISPR Therapeutics Takeover Talk And Investor Questions - Sahm
HighTower Advisors LLC Reduces Stake in CRISPR Therapeutics AG $CRSP - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
FDA Draft Guidance Puts CRISPR Therapeutics Gene Editing Outlook In Focus - Sahm
Crispr Therapeutics AG Surges on Takeover Buzz and Hype - TipRanks
JPMorgan Chase & Co. Buys 294,222 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics Takeover Chatter With Vertex Puts Investor Tradeoffs In Focus - Sahm
Here’s What Analysts Are Saying About CRISPR Therapeutics AG (CRSP) - Yahoo Finance
CRISPR Therapeutics Hits Day High with 11.85% Surge in Stock Price - Markets Mojo
CRISPR Therapeutics Shares Surge on Strong Earnings and Pipeline Growth - Intellectia AI
CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch - TechStock²
Crispr Therapeutics (CRSP) Shares Surge on Takeover Speculation - GuruFocus
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 11.2%Still a Buy? - MarketBeat
Why Is CRISPR Therapeutics Stock Surging Thursday? - Benzinga
Crispr Therapeutics (CRSP) Rumored in M&A Discussions Once More - GuruFocus
Rumor Mill Sends Crispr Therapeutics Shares Climbing Again - TipRanks
Assessing CRISPR Therapeutics (CRSP) Valuation After FDA Draft Guidance And Recent Weak Earnings - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Should You Buy Shares of CRISPR Therapeutics in February? - aol.com
CRISPR Therapeutics AG (CRSP) Stock Analysis: Unveiling A 57% Potential Upside - DirectorsTalk Interviews
CRISPR Therapeutics AG Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Versant Venture Management LLC Decreases Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
FDA's New Framework Could Benefit CRISPR Therapeutics (CRSP) - GuruFocus
(CRSP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
CRISPR Therapeutics gains after earnings as pipeline hope grows - MSN
Rare disease pharmas could benefit from FDA guidance to accelerate development - Seeking Alpha
Volume Report: Will CRISPR Therapeutics AG benefit from sector rotation2025 Technical Overview & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
O Neil Global Advisors Inc. Acquires Shares of 168,715 CRISPR Therapeutics AG $CRSP - MarketBeat
How FDA RMAT Status For Zugo-cel Amid Wider Losses At CRISPR Therapeutics (CRSP) Has Changed Its Investment Story - simplywall.st
Vestmark Advisory Solutions Inc. Has $15.49 Million Stake in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells $111,048.96 in Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells $366,324.86 in Stock - MarketBeat
CRISPR Therapeutics (CRSP) CEO sells shares to cover RSU taxes - Stock Titan
Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off? - The Motley Fool
First Week of October 16th Options Trading For CRISPR Therapeutics (CRSP) - Nasdaq
The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices - The Motley Fool
What’s next for CRISPR Therapeutics AG stockJuly 2025 Setups & Verified Entry Point Detection - mfd.ru
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street - AOL.com
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows - sharewise.com
Casgevy Rollout And Pipeline Progress Reshape CRISPR Therapeutics Investment Case - Yahoo Finance
Breakout Move: Will CRISPR Therapeutics AG benefit from sector rotationJuly 2025 Selloffs & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
CRISPR Therapeutics touts zugo-cel CAR-T gains, eyes autoimmune expansion at Citi oncology summit - MarketBeat
Crispr Therapeutics: Very High Risk, But Even Higher Potential Reward (NASDAQ:CRSP) - Seeking Alpha
Is CRISPR Therapeutics (CRSP) Turning CASGEVY Momentum Into a Broader Gene-Editing Platform Edge? - Sahm
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Galapagos (GLPG) and West Pharmaceutical Services (WST) - The Globe and Mail
Vertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market Crash - AOL.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Moderna (MRNA) and Disc Medicine (IRON) - The Globe and Mail
CRISPR Therapeutics AG (CRSP) - DirectorsTalk Interviews
4.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):